A technic is described for determining mean circulation time, cardiac output, and central blood volume by use of graded dosages of sodium dehydrocholate (Decholin) administered into a peripheral vein. The indicator-dilution curves derived by the technic were compared with radiopotassium-dilution curves These concepts were tested experimentally by (1) determination indirectly of the blood concentrations of Decholin associated with the appearance and disappearance of the bitter taste, (2) determination of these times of onset and offset of taste following injections of 3 graded doses of Decholin, (3) construction of Decholin-dilution curves from the data on circulation times and blood concentrations at taste threshold, and finally (4) comparison of the results obtained from these curves with results obtained from radiopotassium-dilution studies carried out simultaneously. Comparisons of curve contour, cardiac output, central blood volume, and mean circulation time were made in 12 patients with and without cardiovascular disease. The correlation between the isotope and Decholin results was surprisingly good and indicates that the Decholin method is capable of providing more information than has been obtained in the past.
T HE determination of arm-to-tongue circulation times by the sodium dehydrocholate (Decholin) method has a long history of clinical use. Still it has provided only limited quantitative or diagnostic information about the circulation and, for this reason, has been supplanted to a considerable extent by more complex methods. However, during the course of simultaneous radiopotassium-dilution curve and angiocardiographic studies in patients with rheumatic heart disease, we employed the times of appearance and disappearance of the Decholin taste to decide the timing of film exposures. It soon became apparent that we could frequently differentiate between mitral stenosis and insufficiency as well from the "Decholin" times as we could from the subsequently obtained dilution curves or Diodrast opacification patterns. This finding led us to appreciate that the Decholin test is fundamentally an application of the indicator-dilution principle in which Decholin serves as an indicator providing 2 subjective end points, the times of appearance and disappearance of the characteristic bitter taste. Therefore, we considered that these end points might be related to determinable, relatively constant blood concentrations of Decholin; if so, we might obtain multiple onset and From The Robinette Foundation, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa. This research was supported by grants-in-aid from the American Heart Association, the Atomic Energy Commission, and the Lycoming (Pa.) County Heart Association.
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Dr. Heiman is a Trainee of the National Heart Institute. 245 offset times from multiple injections of graded doses of Decholin. These various times might then be appropriately related to the proper concentration coordinates so as to give adequate data for complete construction of an indicator-dilution curve. Such a curve would of course provide the same quantitative information on cardiac output and central blood volume as are provided by conventional dye and isotope-dilution technics. These concepts were tested experimentally by (1) determination indirectly of the blood concentrations of Decholin associated with the appearance and disappearance of the bitter taste, (2) determination of these times of onset and offset of taste following injections of 3 graded doses of Decholin, (3) construction of Decholin-dilution curves from the data on circulation times and blood concentrations at taste threshold, and finally (4) Mleier.4 These assumptions, of course, were to be tested indirectly by the comparison of I)echolin and K42 results. Then, assuming that D)echolin fulfills these requirements, if onset and offset of the subjective taste occur at known constant blood (concentrations of Deeholin, these 2 concentration-time coordinates establish 2 points on a dilution curve. The constant relationship of blood concentration to taste was experimentally established as (lescribed in the results. Then, assuming constant cardiac output and central volumes, a second injection of a larger (lose of Decholin will give a second curve of exactly the same (parallel) contour as that with the smaller (lose, but one with relatively higher concentration levels at every point on the curve in proportion to the size of the 2 (loses. Thus, the onset and offset times of taste will be at lower points on the second curve contour as compared to initial values as plotted on the first curve because of the unchanged concentration of Decholin required for threshold of taste. These second points can be extral)olated so as to become points on the first (or a common) curve by the process of placing the second points at the time intercel)ts experimentally deter-CONN, HEIMAN, AND JOYNER 
DiscussioN-
The results indicate that a surprisingly accurate indicator-dilution curve can be constructed, at least in many patients, from recordings of the times of appearance and disappearance of the bitter taste following antecubital injections of 3 graded dosages of Decholin. Consequently, surprisingly accurate results for cardiac output, mean circulation time, and central volume are also obtained from these currves with the general limitations of any indicator-dilution method and the specific limitations imposed by the technic employed. The pulmonary mixing volume' and the amount of valvular regurgitant blood flow4 can also be calculated subject to the same restrictions and the validity of those methods. With the K42 method taken as a fixed standard (i.e., one with no random or systematic error), it appears that the Decholin technic gives results for circulation time, blood flow, and central blood volume with a random variability of the order of 15-20 per cent (S.D.) and no demonstrated systematic error in a patient group such as ours. Since the K42 method obviously has some variability itself, the true standard deviation is presumably even somewhat less. With more extensive testing it seems likely that a significant systematic underestimation of flow can be demonstrated under conditions of severely prolonged circulation times.
The following matters are those that we believe provide the major sources of error. The hemodynamic state of the subject and the speed of Decholin injection, must be essentially constant in order that the 3 determinations can be correlated properly. Second, the test has subjective end points and the patients sometimes do not appreciate the disappearance of the Decholin taste as well as its appearance. Therefore, considerable care must be exerted in making as certain as possible that the recorded "disappearance" times are valid. Eveni so, gross discrepancies sometimes occur, which in our studies could be resolved only by drawing the best fit through the experimental points. Third, when mixing volumes are large and blood flow is slow, the concentration critical for taste may not be reached, especially with the smallest doses. Under these circumstances injections containing larger amounts are required to obtain the usual number of points. These amounts may be undesirably large. Fourth, since the greatest accuracy in curve construction can be obtained, in most instances, by treating the terminal portion of the slope as a decreasing exponential, unduly flattened slopes may be obtained in patients with prolonged circulation times. This occurs simply because it is impossible to correct properly for recirculating material. In these patients even though the proper appearance-disappearance times are recorded, the true primary dilution curve may be difficult or impossible to reconstruct. Here the main effect will be a systematic error with calculated output too low and mean circulation times too long. Nine patients, 6 with disseminated lupus erythematosus and 3 with periarteritis nodosa, have been treated with metacortandracin. One patient with periarteritis nodosa died while under treatment. The autopsy showed extensive arterial involvement, both visceral and peripheral. The most remarkable feature in the histologic study was the lack of inflammatory process noted in the diseased arteries. The inference from these studies is that, if this patient had been treated in the early phase of the disease, the outcome would have been more favorable. The other 2 cases of periarteritis nodosa have been converted from very ill people to a status of employability. All 6 patients with disseminated lupus erythematosus had previously been treated with either cortisone or corticotropin. All have done much better with metacortandracin. However, in no instance have the L.E. cells disappeared from the bone marrow or from the peripheral blood. All 6 cases carry on their usual activities with little or no restriction. The capacity to tolerate a normal diet, without salt restriction or the addition of the large, gastric-disturbing doses of potassium required with the use of other steroids, is appreciated by these people. The initial dose was 10 mg. every 8 hours in all cases except 1. The dose was decreased by 5 mg. every 5 days until the smallest amount required for maintenance was reached. It was usually 15 to 20 mg./day. All these patients with 1 exception have been observed under treatment for 60 to 120 days. Although the short-term treatment has been favorable, more time will have to elapse before a conclusive opinion can be reached as to long-term treatment of the collagen diseases with this new compound.
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